### Form 605

### Corporations Act 2001 Section 671B

### Notice of ceasing to be a substantial holder

To Company Name/Scheme	CYCLOPHARM LIMITED
ACN/ARSN	116 931 250

### 1. Details of substantial holder (1)

Name LLOYDS & CASANOVE INVESTMENT PARTNERS LIMITED

ACN/ARSN (if applicable) N/A

The holder ceased to be a substantial holder on 30/12/2016The previous notice was given to the company on 03/05/2013The previous notice was dated 02/05/2013

### 2. Changes in relevant interests

Particulars of each change in, or change in the nature of, a relevant interest (2) of the substantial holder or an associate (3) in voting securities of the company or scheme, since the substantial holder was last required to give a substantial holding notice to the company or scheme are as follows:

Date of change	Person whose relevant interest changed	Nature of change (4)	Consideration given in relation to change (5)	Class (6) and number of securities affected	Person's votes affected
		REFER TO ANNEXURE A			

### 3. Changes in association

The persons who have become associates (3) of, ceased to be associates of, or have changed the nature of their association (7) with, the substantial holder in relation to voting interests in the company or scheme are as follows:

Name and ACN/ARSN (if applicable)	Nature of association
Not applicable	

### 4. Addresses

The addresses of persons named in this form are as follows:

Name	Address
LLOYDS & CASANOVE INVESTMENT PARTNERS LIMITED	PATERNOSTER HOUSE, 65 ST PAULS CHURCHYARD, LONDON EC4M 8AB, UNITED KINGDOM

### Signature

print name

K. MILLINER

capacity

sign here

date 16

102 / 2017

### **DIRECTIONS**

- (1) If there are a number of substantial holders with similar or related relevant interests (eg. a corporation and its related corporations, or the manager and trustee of an equity trust), the names could be included in an annexure to the form. If the relevant interests of a group of persons are essentially similar, they may be referred to throughout the form as a specifically named group if the membership of each group, with the names and addresses of members is clearly set out in paragraph 4 of the form.
- (2) See the definition of "relevant interest" in sections 608 and 671B(7) of the Corporations Act 2001.
- (3) See the definition of "associate" in section 9 of the Corporations Act 2001.
- (4) Include details of:
  - (a) any relevant agreement or other circumstances because of which the change in relevant interest occurred. If subsection 671B(4) applies, a copy of any document setting out the terms of any relevant agreement, and a statement by the person giving full and accurate details of any contract, scheme or arrangement, must accompany this form, together with a written statement certifying this contract, scheme or arrangement; and
  - (b) any qualification of the power of a person to exercise, control the exercise of, or influence the exercise of, the voting powers or disposal of the securities to which the relevant interest relates (indicating clearly the particular securities to which the qualification applies).

See the definition of "relevant agreement" in section 9 of the Corporations Act 2001.

- (5) Details of the consideration must include any and all benefits, money and other, that any person from whom a relevant interest was acquired has, or may, become entitled to receive in relation to that acquisition. Details must be included even if the benefit is conditional on the happening or not of a contingency. Details must be included of any benefit paid on behalf of the substantial holder or its associate in relation to the acquisitions, even if they are not paid directly to the person from whom the relevant interest was acquired.
- (6) The voting shares of a company constitute one class unless divided into separate classes.
- (7) Give details, if appropriate, of the present association and any change in that association since the last substantial holding notice.

### ANNEXURE A

# This is Annexure A Page 1 of 1 - Cyclopharm Limited (ACN: 116 931 250)

## 3 Changes in relevant interests

10,949,966	10,949,966	\$ 9,691,311			Total
10,568,470	10,568,470	\$ 9,617,307.70	Off Market disposal	Lloyds & Casanove Investment Partners Ltd	30.12.16
182,391	182,391	\$ 36,679	On Market purchase	Lloyds & Casanove Investment Partners Ltd	28.08.13
18,409	18,409	\$ 3,682	On Market purchase	Lloyds & Casanove Investment Partners Ltd	21.08.13
14,000	14,000	\$ 2,800	On Market purchase	Lloyds & Casanove Investment Partners Ltd	20.08.13
35,200	35,200	\$ 7,079	On Market purchase	Lloyds & Casanove Investment Partners Ltd	13.08.13
82,400	82,400	\$ 14,914	On Market purchase	Lloyds & Casanove Investment Partners Ltd	22.05.13
12,746	12,746	\$ 2,307	On Market purchase	Lloyds & Casanove Investment Partners Ltd	14.05.13
35,233	35,233	\$ 6,342	On Market purchase	Lloyds & Casanove Investment Partners Ltd	07.05.13
1,117	1,117	\$ 201	On Market purchase	Lloyds & Casanove Investment Partners Ltd	02.05.13
Person's votes affected	Class and number of securities affected	Consideration given in relation to change	Nature of change	Person whose relevant interest changed	Date of change

Name: K.MILLING Capa Signed: Date:

Director

16.02.17